Epizyme

IPO

Transformative therapies against novel epigenetic targets

Public · Cambridge, United States · Founded 2007 · $154.0M raised

Employees
201–500
Founded
2007
Business Model
B2B
Total Funding
$154.0M
Last Round
$100.0M Growth EquityNov 2019
Rounds
3
Type
Public

About

Epizyme is a commercial-stage biopharmaceutical company creating innovative drugs for major diseases based on epigenetics discoveries. It developed therapies targeting epigenetic targets for cancer and was acquired by Ipsen.

Summary

Epizyme is a Biotech company based in Cambridge, United States, founded in 2007. It has raised $154.0M in total across 3 rounds, most recently a $100.0M Growth Equity round in Nov 2019. Investors include Royalty Pharma, Bay City Capital and MPM Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Growth EquityRoyalty Pharma InvestmentNov 2019
$100.0M

Sign up to see all 4 rounds

Series A through Growth Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Epizyme on Indexed.vc
<a href="https://indexed.vc/companies/epizyme"><img src="https://indexed.vc/api/badge/company/epizyme" alt="Epizyme on Indexed.vc" width="260" height="76" /></a>